mRNA Delivery Platform Based on Bacterial Outer Membrane Vesicles for Tumor Vaccine

Xiaoyu Gao; Yao Li; Guangjun Nie; Xiao Zhao

doi:10.21769/BioProtoc.4774

mRNA Delivery Platform Based on Bacterial Outer Membrane Vesicles for Tumor Vaccine

Bio Protoc. 2023 Jul 5;13(13):e4774. doi: 10.21769/BioProtoc.4774.

Authors

Xiaoyu Gao^{1

2}, Yao Li^{1

3}, Guangjun Nie^{1

2}, Xiao Zhao^{1

2

4}

Affiliations

¹ CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, 11 Beiyitiao, Zhongguancun, Beijing, 100190, China.
² University of Chinese Academy of Sciences, Beijing, 100049, China.
³ Institute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, China.
⁴ IGDB-NCNST Joint Research Center, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, 100101, China.

Abstract

The rapid display and delivery method for customized tumor mRNA vaccines is limited. Herein, bacteria-derived outer membrane vesicles (OMVs) are employed as an mRNA delivery platform by surface engineering of an RNA-binding protein, L7Ae. OMV-L7Ae can rapidly adsorb boxC/D sequence-labeled mRNA antigens through L7Ae-boxC/D binding and deliver them into HEK-293T and dendritic cells. This platform provides an mRNA delivery technology distinct from lipid nanoparticles (LNPs) for personalized mRNA tumor vaccination and with a Plug-and-Display strategy suitable for rapid preparation of the personalized mRNA tumor vaccine against varied tumor antigens. Key features OMVs are employed as an mRNA delivery platform through L7Ae-boxC/D binding.

Keywords: BoxC/D; Cancer immunotherapy; Outer membrane vesicles; RNA binding protein; Rapid display; mRNA vaccines.